Signaturefd, LLC Bluebird Bio, Inc. Transaction History

Signaturefd, LLC

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$1.32 - $4.83 $1,917 - $7,017	1,453 Added 286.59%	1,960 $2,000
Q3 2023 Nov 03, 2023	BUY	$3.02 - $4.05 $36 - $48	12 Added 2.42%	507 $1,000
Q2 2023 Aug 01, 2023	BUY	$2.79 - $5.03 $502 - $905	180 Added 57.14%	495 $1,000
Q1 2023 Apr 28, 2023	SELL	$3.14 - $8.22 $383 - $1,002	-122 Reduced 27.92%	315 $1,000
Q4 2022 Jan 27, 2023	BUY	$5.77 - $8.49 $848 - $1,248	147 Added 50.69%	437 $3,000
Q3 2022 Nov 08, 2022	BUY	$3.75 - $7.39 $1,087 - $2,143	290 New	290 $2,000
Q2 2022 Aug 10, 2022	SELL	$2.94 - $5.23 $758 - $1,349	-258 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$4.07 - $10.6 $28 - $74	7 Added 2.79%	258 $1,000
Q3 2021 Oct 28, 2021	SELL	$11.24 - $21.0 $13,870 - $25,914	-1,234 Reduced 83.1%	251 $5,000
Q2 2021 Jul 26, 2021	BUY	$18.04 - $22.09 $829 - $1,016	46 Added 3.2%	1,485 $47,000
Q1 2021 Apr 30, 2021	BUY	$16.59 - $33.89 $182 - $372	11 Added 0.77%	1,439 $43,000
Q4 2020 Feb 11, 2021	BUY	$27.5 - $37.92 $35,942 - $49,561	1,307 Added 1080.17%	1,428 $62,000
Q3 2020 Nov 03, 2020	BUY	$34.44 - $43.75 $1,170 - $1,487	34 Added 39.08%	121 $7,000
Q2 2020 Jul 30, 2020	BUY	$27.12 - $45.97 $2,006 - $3,401	74 Added 569.23%	87 $5,000
Q1 2020 Apr 23, 2020	SELL	$26.16 - $63.5 $994 - $2,413	-38 Reduced 74.51%	13 $1,000
Q4 2019 Feb 05, 2020	BUY	$46.96 - $61.67 $2,394 - $3,145	51 New	51 $4,000
Q1 2018 May 08, 2018	SELL	$105.8 - $150.94 $174,887 - $249,503	-1,653 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$81.25 - $130.7 $134,306 - $216,047	1,653	1,653 $294,000

142

63.2M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $605M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.